In this study, a multifunctional carrier-free nanoplatform composed of curcumin and indocyanine green self-assembled into uniform spherical nanoparticles, coated with polydopamine, and functionalized with anti-CD33 antibodies is used for targeted AML therapy. Indocyanine green drives stable co-assembly with curcumin, while the polydopamine layer improves photostability, enables pH-responsive release in acidic tumor-like environments, and provides versatile chemistry for antibody conjugation. CD33 targeting confers selective uptake via receptor-mediated endocytosis into AML cells. In vitro studies demonstrated that Ab@pDCur–ICG NPs achieved significantly higher uptake and cytotoxicity in CD33-positive cells than in CD33-negative controls, with uptake reduced upon antibody blocking. Under near-infrared irradiation, the nanoparticles produced synergistic chemo–photothermal effects, yielding the highest apoptotic response in CD33-positive leukemia cells. Notably, the formulation displayed high structural uniformity compared to typical carrier-free assemblies, supporting enhanced stability and reproducibility. This targeted, multimodal nanoplatform integrates high drug loading, selective delivery, and synergistic therapy, representing a promising strategy to improve AML outcomes and potentially extend to other hematological malignancies.
27 July 2026 in International Journal of Pharmaceutics